
Nuvectis Pharma, Inc.: updates and filings
Price
$19.39
November 20, 2026Market cap $667M
What Ploutos Investor adds for Nuvectis Pharma
Part of Ploutos Investor, €9.99 a month
- The full history: 5 fiscal years, from 2021
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
August 2026
June 2026
May 2026
February 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 4, 2026Results of operationsForm8-K
- Aug 28, 2026FilingFormEFFECT
- Aug 21, 2026Shelf registration for future offeringsFormS-3
- Aug 21, 2026Other material eventsForm8-K
- Aug 6, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 4, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 4, 2026Results of operationsForm8-K
- Jun 30, 2026Material agreement entered, other material eventsForm8-K
- Jun 29, 2026Other material eventsForm8-K
- Jun 23, 2026Material agreement entered, other material eventsForm8-K
- Jun 12, 2026Shareholder voteForm8-K
- May 5, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 5, 2026Results of operationsForm8-K
- Apr 27, 2026Additional annual meeting materialFormDEFA14A
- Apr 27, 2026Annual meeting proxy statementFormDEF 14A
- Feb 20, 2026FilingFormEFFECT
- Feb 18, 2026Correspondence with the SECFormCORRESP
- Feb 18, 2026Letter from the SECFormUPLOAD
- Feb 13, 2026Shelf registration for future offeringsFormS-3
- Feb 11, 2026Results of operationsForm8-K
- Feb 11, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Nov 4, 2025Results of operationsForm8-K
- Nov 4, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Sep 25, 2025Officer or director changeForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 4, 2026 | 8-K | Results of operations | Document |
| Aug 28, 2026 | EFFECT | Filing | Document |
| Aug 21, 2026 | S-3 | Shelf registration for future offerings | Document |
| Aug 21, 2026 | 8-K | Other material events | Document |
| Aug 6, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 4, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 4, 2026 | 8-K | Results of operations | Document |
| Jun 30, 2026 | 8-K | Material agreement entered, other material events | Document |
| Jun 29, 2026 | 8-K | Other material events | Document |
| Jun 23, 2026 | 8-K | Material agreement entered, other material events | Document |
| Jun 12, 2026 | 8-K | Shareholder vote | Document |
| May 5, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 5, 2026 | 8-K | Results of operations | Document |
| Apr 27, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 27, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Feb 20, 2026 | EFFECT | Filing | Document |
| Feb 18, 2026 | CORRESP | Correspondence with the SEC | Document |
| Feb 18, 2026 | UPLOAD | Letter from the SEC | Document |
| Feb 13, 2026 | S-3 | Shelf registration for future offerings | Document |
| Feb 11, 2026 | 8-K | Results of operations | Document |
| Feb 11, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Nov 4, 2025 | 8-K | Results of operations | Document |
| Nov 4, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Sep 25, 2025 | 8-K | Officer or director change | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 30, 2021.
The full analysis
What do Nuvectis Pharma's filings show?
The filings are where every one of Nuvectis Pharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.